{"paper_id":"7ecdb892-8cf7-4798-8cb9-fd0a2ebb0656","body_text":"Single-Cell Transcriptomic Identification of Drug Repurposing Candidates for Endometriosis via Endometrial Biopsy scRNA-seq\nAuthors/Creators\n- 1. Ritschel Research\n- 2. Anthropic\nDescription\nA computational drug repurposing study of human endometriosis using single-cell RNA sequencing data (GSE179640, 47,957 endometrial biopsy cells, 29 endometriosis / 3 control samples). scVI batch correction resolved 31 Leiden clusters annotated as 10 cell types including stromal fibroblasts, endometrial epithelial cells, macrophages, NK cells, T cells, mast cells, smooth muscle, endothelial, B cells, and plasma cells. Wilcoxon differential expression (Endo vs Control) identified 500 significant genes dominated by a stromal fibroblast activation signature (COL1A1, FN1, SPARC, TAGLN). ChEMBL screening (pChEMBL≥6.0) across 184 druggable targets yielded 20,510 scored compounds; 20,117 confirmed novel via PubChem. Top candidates: CHEMBL5653589 (190.34, 18 targets), LESTAURTINIB (168.64, 16 targets), CHEMBL3752910 (118.90, 11 targets). Seven cross-disease watchlist compounds confirmed. CHEMBL5653589 ranks #1 across 8 independent Ritschel Research disease pipelines. Authors: Glen Charles Ritschel (Ritschel Research, Tega Cay SC) and Claude (Anthropic, San Francisco CA).\nFiles\nFiles\n(14.5 kB)\n| Name | Size | Download all |\n|---|---|---|\n|\nmd5:56ca46f0e52046ee9525a5c8f2e32b17\n|\n14.5 kB | Download |","source_license":"CC0","license_restricted":false}